Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jon Jones

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Annals of the American Thoracic Society|July 12, 2024
Effectiveness and Safety of an Emergency Department Code Sepsis Protocol: A Pragmatic Clinical TrialIthan D Peltan, Joseph R Bledsoe, Jason R Jacobs, et al.
Urologia Internationalis|July 21, 2021
Perioperative Outcomes of Transurethral Resection, Open Prostatectomy, and Laser Therapy in the Surgical Treatment of Benign Prostatic Obstruction: A "Real-World" Data Analysis from the URO-Cert Prostate CentersJan Herden, Thomas Ebert, Daniel Schlager, et al.
Science Translational Medicine|March 29, 2019
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cellsEric L Smith, Kim Harrington, Mette Staehr, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Annals of the American Thoracic Society|July 12, 2024
Effectiveness and Safety of an Emergency Department Code Sepsis Protocol: A Pragmatic Clinical TrialIthan D Peltan, Joseph R Bledsoe, Jason R Jacobs, et al.
Urologia Internationalis|July 21, 2021
Perioperative Outcomes of Transurethral Resection, Open Prostatectomy, and Laser Therapy in the Surgical Treatment of Benign Prostatic Obstruction: A "Real-World" Data Analysis from the URO-Cert Prostate CentersJan Herden, Thomas Ebert, Daniel Schlager, et al.
Science Translational Medicine|March 29, 2019
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cellsEric L Smith, Kim Harrington, Mette Staehr, et al.
Pageof 6